Latest insights into oncolytic viro-immunotherapy with vesicular stomatitis virus

Manuela Lizarralde-Guerrero; David Olagnier; Fernando Aranda; Maria Chiara Maiuri; Guido Guido Kroemer; Jonathan Pol

doi:10.1016/j.smim.2025.101996

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2018

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

Jonathan Pol, Sarah Lévesque, Samuel T. Workenhe, Shashi Gujar, Fabrice Le Bœuf, Derek R. Clements, Jean‐Eudes Fahrner, Laetitia Fend, John C. Bell, Karen Mossman, Jitka Fučíková, Radek Špíšek, Laurence Zitvogel, Guido Guido Kroemer, Lorenzo Galluzzi

Article2007

MyD88 protects from lethal encephalitis during infection with vesicular stomatitis virus

Karl S. Lang, Alexander A. Navarini, Mike Recher, Philipp A. Lang, Mathias Heikenwälder, Barbara Stecher, Andreas Bergthaler, Bernhard Odermatt, Akira Shizuo, Kenya Honda, Hans Hengartner, Rolf M. Zinkernagel

European Journal of Immunology

Article2015

Vesicular stomatitis virus (VSV) as a paradigm for predicting antiviral activity against Ebola virus (EBOV)

De Clercq Erik

Article2015

First oncolytic virus approved for melanoma immunotherapy

Jonathan Pol, Guido Guido Kroemer, Lorenzo Galluzzi

Article1969

Local and Systemic Protection by Synthetic Polyanionic Interferon Inducers in mice against Intranasal Vesicular Stomatitis Virus

De Clercq Erik, T. C. Merigan